Astellas sues FDA over bioequivalence standards for tacrolimus ANDAs and seeks injunction
This article was originally published in Scrip
Executive Summary
Astellas Pharma has filed a complaint in the US District Court for the District of Columbia, alleging that the FDA "acted unlawfully" in approving an ANDA for generic Prograf (tacrolimus), its immunosuppressant.